

Francesco Puppo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4977664/publications.pdf>

Version: 2024-02-01

70
papers

2,972
citations

172457

29
h-index

175258

52
g-index

72
all docs

72
docs citations

72
times ranked

3829
citing authors

#	ARTICLE	IF	CITATIONS
1	Soluble HLA class I molecules induce apoptosis in T and NK CD8 ⁺ cells and inhibit cytotoxic T cell activity through CD8 ligation. <i>European Journal of Immunology</i> , 2003, 33, 125-134.	2.9	338
2	Emerging role of vitamin D in autoimmune diseases: An update on evidence and therapeutic implications. <i>Autoimmunity Reviews</i> , 2019, 18, 102350.	5.8	186
3	Infection risk associated with anti-TNF- α agents: a review. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 571-582.	2.4	153
4	Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. <i>Annals of Allergy, Asthma and Immunology</i> , 2005, 95, 38-44.	1.0	115
5	Sjögren's syndrome: a systemic autoimmune disease. <i>Clinical and Experimental Medicine</i> , 2022, 22, 9-25.	3.6	115
6	Serum HLA class I antigens: markers and modulators of an immune response?. <i>Trends in Immunology</i> , 1995, 16, 124-127.	7.5	113
7	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis, etc.)	5.8	107
8	Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8 ⁺ Fas (CD95) ⁺ T lymphocytes. <i>International Immunology</i> , 2000, 12, 195-203.	4.0	98
9	IL-33/IL-31 Axis in Immune-Mediated and Allergic Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5856.	4.1	91
10	Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 199-208.	5.6	90
11	TNF- α Gene Polymorphisms: Association with Disease Susceptibility and Response to Anti-TNF- α Treatment in Psoriatic Arthritis. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2503-2509.	0.7	89
12	The antiphospholipid syndrome: from pathophysiology to treatment. <i>Clinical and Experimental Medicine</i> , 2017, 17, 257-267.	3.6	84
13	Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: Current views upon safety and immunogenicity. <i>Autoimmunity Reviews</i> , 2014, 13, 75-84.	5.8	76
14	Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 43-52.	2.4	72
15	Apoptosis of Antigen-Specific T Lymphocytes upon the Engagement of CD8 by Soluble HLA Class I Molecules Is Fas Ligand/Fas Mediated: Evidence for the Involvement of p56 ^{lck} , Calcium Calmodulin Kinase II, and Calcium-Independent Protein Kinase C Signaling Pathways and for NF- κ B and NF-AT Nuclear Translocation. <i>Journal of Immunology</i> , 2005, 175, 7244-7254.	0.8	66
16	Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference. <i>Autoimmunity Reviews</i> , 2015, 14, 692-702.	5.8	63
17	Genetic factors and systemic sclerosis. <i>Autoimmunity Reviews</i> , 2016, 15, 427-432.	5.8	59
18	Free radicals and endothelial dysfunction: Potential positive effects of TNF- α inhibitors. <i>Redox Report</i> , 2013, 18, 95-99.	4.5	55

#	ARTICLE	IF	CITATIONS
19	Potential use of TNF- $\hat{\pm}$ inhibitors in systemic sclerosis. <i>Immunotherapy</i> , 2014, 6, 283-289.	2.0	53
20	Pharmacogenetics of etanercept: role of TNF- $\hat{\pm}$ gene polymorphisms in improving its efficacy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 1703-1710.	3.3	52
21	Emerging biologic drugs for the treatment of rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2005, 4, 537-541.	5.8	51
22	In vitro immunosuppressive activity of soluble HLA class I and Fas ligand molecules:do they play a role in autologous blood transfusion?. <i>Transfusion</i> , 2001, 41, 988-996.	1.6	45
23	Increased level of serum HLA class I antigens in HIV infection correlation with disease progression. <i>Human Immunology</i> , 1994, 40, 259-266.	2.4	43
24	Increased levels of interleukin-10 in saliva of Sjögren's syndrome patients. Correlation with disease activity. <i>Clinical and Experimental Medicine</i> , 2004, 4, 148-151.	3.6	43
25	Update upon the infection risk in patients receiving TNF alpha inhibitors. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 219-229.	2.4	37
26	HLA-G Expressing Immune Cells in Immune Mediated Diseases. <i>Frontiers in Immunology</i> , 2020, 11, 1613.	4.8	36
27	Behavior of non-classical soluble HLA class G antigens in human immunodeficiency virus 1-infected patients before and after HAART: Comparison with classical soluble HLA-A, -B, -C antigens and potential role in immune-reconstitution. <i>Clinical Immunology</i> , 2009, 133, 238-244.	3.2	34
28	Fas, Fas ligand,and transfusion immunomodulation. <i>Transfusion</i> , 2001, 41, 416-418.	1.6	33
29	Determination of soluble HLA-G and HLA-A, -B, and -C molecules in pregnancy. <i>Transplantation Proceedings</i> , 1999, 31, 1841-1843.	0.6	30
30	Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis. <i>Modern Rheumatology</i> , 2018, 28, 417-431.	1.8	30
31	HLA-G expression in gastric carcinoma: clinicopathological correlations and prognostic impact. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 425-433.	2.8	27
32	Behavior of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy: An early predictor marker of response?. <i>Journal of Clinical Immunology</i> , 1995, 15, 179-184.	3.8	26
33	Vaccine-preventable infections in Systemic Lupus Erythematosus. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 632-643.	3.3	26
34	Efficacy and safety of etanercept in chronic immune-mediated disease. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 649-661.	2.4	24
35	Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study. <i>Clinical and Experimental Medicine</i> , 2019, 19, 357-366.	3.6	23
36	Use of leflunomide plus TNF- $\hat{\pm}$ inhibitors in rheumatoid arthritis. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 801-804.	2.4	22

#	ARTICLE	IF	CITATIONS
37	Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1173-1179.	2.4	22
38	Soluble HLA-G and HLA-E, -B, -C serum levels in patients with allergic rhinitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 1335-1338.	5.7	21
39	Sublingual immunotherapy reduces soluble HLA-G and HLA-A,-B,-C serum levels in patients with allergic rhinitis. <i>International Immunopharmacology</i> , 2009, 9, 253-257.	3.8	21
40	Simple elisa method for the evaluation of soluble hla class i antigens in human serum. <i>Journal of Clinical Laboratory Analysis</i> , 1991, 5, 278-283.	2.1	19
41	Immunoregulatory Role of HLA-G in Allergic Diseases. <i>Journal of Immunology Research</i> , 2016, 2016, 1-7.	2.2	19
42	22-1/4-free HLA class I heavy chain levels in sera of healthy individuals. Lack of association with 22-1/4-associated HLA class I heavy chain levels and HLA phenotype. <i>Tissue Antigens</i> , 1999, 53, 253-262.	1.0	18
43	Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 295-305.	2.4	18
44	Stem cells therapy in acute myocardial infarction: a new era?. <i>Clinical and Experimental Medicine</i> , 2021, 21, 231-237.	3.6	16
45	Expression of membrane-bound human leucocyte antigen-G in systemic sclerosis and systemic lupus erythematosus. <i>Human Immunology</i> , 2020, 81, 162-167.	2.4	15
46	Effects of AntagomiRs on Different Lung Diseases in Human, Cellular, and Animal Models. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3938.	4.1	13
47	Soluble human leukocyte antigen-G serum levels in patients with acquired immune deficiency syndrome affected by different disease-defining conditions before and after antiretroviral treatment. <i>Human Immunology</i> , 2011, 72, 712-6.	2.4	12
48	Pharmacogenetics and Future Therapeutic Scenarios: What Affects the Prediction of Response to Treatment with Etanercept?. <i>Drug Development Research</i> , 2014, 75, S7-S10.	2.9	12
49	Long-term treatment of rheumatoid arthritis with adalimumab. <i>Open Access Rheumatology: Research and Reviews</i> , 2013, 5, 43.	1.6	11
50	Evaluation of membrane-bound and soluble forms of human leucocyte antigen-G in systemic sclerosis. <i>Clinical and Experimental Immunology</i> , 2018, 193, 152-159.	2.6	11
51	Immunogenicity of infliximab and adalimumab. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 343-345.	2.4	11
52	Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-1± and ribavirin treatment: potential role as markers of response to antiviral therapy. <i>Clinical and Experimental Medicine</i> , 2017, 17, 93-100.	3.6	10
53	Serum HLA class I antigen levels in allogeneic bone marrow transplantation: a possible marker of acute GVHD. <i>Bone Marrow Transplantation</i> , 1996, 17, 753-8.	2.4	10
54	Behavior of serum human major histocompatibility complex class I antigen levels in human immunodeficiency virus-infected patients during antiretroviral therapy: Correlation with clinical outcome. <i>Human Immunology</i> , 2007, 68, 894-900.	2.4	8

#	ARTICLE	IF	CITATIONS
55	Beneficial effects of long-term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis. <i>Journal of International Medical Research</i> , 2016, 44, 85-89.	1.0	8
56	Allergen-driven HLA-G expression and secretion in peripheral blood mononuclear cells from allergic rhinitis patients. <i>Human Immunology</i> , 2016, 77, 1172-1178.	2.4	8
57	Efficacy of cilostazol for the treatment of Raynaud's phenomenon in systemic sclerosis patients. <i>Clinical and Experimental Medicine</i> , 2016, 16, 407-412.	3.6	8
58	Major histocompatibility gene products and human immunodeficiency virus infection. <i>Translational Research</i> , 1991, 117, 91-100.	2.3	8
59	Soluble beta2-mu-associated and beta2-mu-free HLA class I heavy chain serum levels in interferon-alpha nonresponder chronic hepatitis C patients. <i>Markers of immune activation, and response to antiviral retreatment. Journal of Clinical Immunology</i> , 2000, 20, 486-490.	3.8	7
60	Esophageal baseline impedance levels allow the identification of esophageal involvement in patients with systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 569-574.	3.4	5
61	Increased β 2-microglobulin-free HLA class I heavy chain serum levels in the course of immune responses to viral antigens and to mismatched HLA antigens. <i>Tissue Antigens</i> , 2000, 55, 333-341.	1.0	4
62	Autoimmune central diabetes insipidus in a patient with ureaplasma urealyticum infection and review on new triggers of immune response. <i>Archives of Endocrinology and Metabolism</i> , 2015, 59, 554-558.	0.6	4
63	Immunoregulatory role of soluble HLA molecules: a new skin for an old subject?. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 1998, 46, 157-60.	2.3	4
64	HLA-G in Allergy: Does It Play an Immunoregulatory Role?. <i>Frontiers in Immunology</i> , 2021, 12, 789684.	4.8	3
65	Quantitative analyses of plasma opsonizing activity and polymorphonuclear cell response during phagocytosis: standardisation of a chemiluminescent method. <i>Apmis</i> , 1996, 104, 500-508.	2.0	1
66	New York Heart Association class associated with imaging is a prognostic mortality risk predictor in interstitial lung diseases. <i>European Review for Medical and Pharmacological Sciences</i> , 2020, 24, 9012-9021.	0.7	1
67	Systemic sarcoidosis with pituitary adenoma. <i>Journal of Clinical Imaging Science</i> , 0, 12, 32.	1.1	1
68	Diagnosis of an unusual case of idiopathic mediastinal fibrosis by 18F-FDG PET/CT. <i>Radiology Case Reports</i> , 2020, 15, 435-436.	0.6	0
69	In-111 octreotide SPECT/CT in the early diagnosis of pulmonary sarcoidosis: A case report. <i>Radiology Case Reports</i> , 2022, 17, 340-343.	0.6	0
70	Distinguishing Features in Systemic Sclerosis Patients with Non-Specific Interstitial Pneumonia and Idiopathic Pulmonary Fibrosis. , 2022, , .		0